WILMINGTON, Del. & SAN FRANCISCO, May 19, 2026
Incyte and Edison Scientific have announced a strategic collaboration aimed at transforming pharmaceutical research and development through the deployment of the Kosmos AI Platform, an advanced artificial intelligence system designed to enhance scientific discovery, translational biology, and clinical development workflows. The partnership marks a major step forward in the growing integration of AI across the global biopharmaceutical industry as companies increasingly rely on machine learning and predictive analytics to accelerate drug development and improve decision-making across complex therapeutic pipelines.
AI Platform to Strengthen Drug Discovery and Development
Under the collaboration, Edison Scientific’s Kosmos AI scientist platform will be integrated across Incyte’s discovery and development lifecycle to create a continuously learning research ecosystem capable of synthesizing experimental, translational, biomarker, and clinical data in real time. According to the companies, the initial deployment will focus on high-impact applications in target discovery, target validation, and translational biology, while supporting researchers in navigating increasingly large and complex biomedical datasets. The companies stated that the AI platform is intended to improve scientific consistency, optimize experimental design, and generate predictive models that could enhance therapeutic performance and long-term pipeline productivity.
Pablo J. Cagnoni, M.D., President and Global Head of Research and Development at Incyte, stated that the company’s vision is to transform its vast clinical and experimental datasets into an intelligent learning system capable of improving every stage of decision-making. He emphasized that the collaboration is not solely focused on accelerating development timelines but also on improving the overall quality of outcomes across Incyte’s expanding research programs. In addition, Patrick Mayes, Ph.D., Executive Vice President and Chief Scientific Officer at Incyte, noted that the integration of AI systems trained on experimental and clinical information could significantly improve result interpretation while creating a feedback loop that continuously strengthens future development programs.
Strategic Push Toward AI-Driven Biopharma Innovation
Advertisement
The collaboration reflects a broader trend across the pharmaceutical sector where AI-driven platforms are increasingly being positioned as core components of next-generation drug discovery infrastructure. Edison Scientific explained that unlike traditional AI analytics models that simply interpret datasets, the Kosmos platform is designed to continuously learn from every experiment, clinical readout, and development decision, enabling the system to evolve over time and provide compounding scientific advantages. Sam Rodriques, Ph.D., Chief Executive Officer of Edison Scientific, described the initiative as a new operating model for the biopharmaceutical industry in which proprietary data becomes a continuously improving competitive asset rather than a static repository of information.
The collaboration also highlights the rapidly expanding role of AI in oncology, immunology, and translational medicine research, areas where Incyte maintains a significant development presence. Industry analysts continue to identify AI-enabled drug discovery as one of the most transformative technologies shaping the future of pharmaceutical R&D, particularly as companies seek to reduce attrition rates, identify novel biomarkers, and accelerate precision medicine strategies. The partnership between Incyte and Edison Scientific further positions both organizations at the forefront of AI-enabled scientific innovation within the global healthcare sector.
Source: Incyte, Edison Scientific press release
